

1 Review

2 Hijacking the Host Immune Cells by Dengue Virus: 3 Molecular Interplay of Receptors and Dengue Virus 4 Envelope

5 ¹Feroza Begum, ^{1,2}Sandeepan Das#, ^{1,2}Debica Mukherjee# and ^{1,2}Upasana Ray*

6 Author affiliations:

7 Feroza Begum: CSIR-Indian Institute of Chemical Biology; 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-
8 700032, West Bengal, India

9 Sandeepan Das: ¹CSIR-Indian Institute of Chemical Biology; 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-
10 700032, West Bengal, India ²Academy of

11 Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India

12 Debica Mukherjee: ¹CSIR-Indian Institute of Chemical Biology; 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-
13 700032, West Bengal, India ²Academy

14 of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India

15 * Correspondence: Correspondence: pasana Ray: Email: ray.upasana@gmail.com, upasana.ray@iicb.res.in,
16 Phone: +91-9781878333

17 ¹CSIR-Indian Institute of Chemical Biology; 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, West
18 Bengal, India

19 ²Academy of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India

20

21 Abstract: dengue virus (DENV), being one of the lethal pathogens in the hot climatic regions of the
22 world, have been extensively studied to decipher its mechanism of pathogenesis and missing links
23 of its life cycle. With respect to the entry of DENV, multiple receptors have been recognised in
24 different cells of the human body. However, scientists still argue whether these identified receptors
25 are the exclusive entry mediators for the virus. Adding to the complexity, DENV has been reported
26 to be infecting multiple organ types in its human host. Also, more than one receptor in a particular
27 cell has been discerned to take part in mediating the ingress of DENV. In this review, we aim to
28 discuss about the different cells of the human immune system that support DENV infection and
29 their corresponding receptors that DENV deploy to gain access to the cells.

30

31 **Keywords:** DENV; tropism; receptors; entry; immune cells

32

33 Introduction

34 The genus *Flavivirus* includes enveloped viruses (approx 50nm in diameter) containing
35 positive sense, single stranded RNA (approx 11kb in size) genome. Dengue virus (DENV) is one such
36 arbovirus having a genome encoding three structural proteins (C, prM/M, E) and seven non
37 structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) [1]. The envelope of the mature
38 virus contains 180 copies of two glycoproteins, prM and E [2]. Depending on the heterogeneity in
39 these two surface proteins, DENV is broadly classified into 4 serotypes and each serotype is further
40 distinguished into different genotypes [3].

41 DENV, being an arbovirus entirely depends on its insect vectors *Aedes aegypti* and *Aedes*
42 *albopictus* for circulation in the environment and ultimately reaches its human host for extensive
43 proliferation.

44 Once DENV gains access to the host, it infects different organs and replicate in multiple cells.
45 DENV exploits various cellular receptors to enter the cells. Although various cellular receptors have

46 been identified as receptors for virus entry, none of them has been recognized as an universal receptor
47 for DENV entry. Here, we will discuss about the immune cells that are known to harbour DENV
48 during the disease progression and the corresponding receptors studied so far. It remains an
49 underexplored field and we are yet to nail down the primary receptor/s involved in the entry process.
50 Better understanding of the receptor usage might further help designing specific antiviral candidate/s
51 against DENV infection.

52 DENV entry receptors in cells of the immune system

53 Dendritic Cells (DCs)

54 Broadly, there are two subsets of DCs found in mammalian system: Interferon (IFN) secreting,
55 blood and lymphoid tissue resident plasmacytoid DC (pDC) and antigen presenting, lymphoid and
56 non-lymphoid tissue resident myeloid or conventional dendritic cells (mDCs or cDCs). The antigen
57 presenting property of DC has been exploited by DENV to disseminate from the skin to various
58 lymphoid organs. Also a common monocyte-DC precursor differentiates to give rise to tissue resident
59 macrophages and monocyte derived DCs (moDC) which are non-conventional DCs [1].

60 The immature DCs (iDCs) particularly in skin (Langerhans cells, dermal cDC and moDC) and
61 in blood have been shown to be more susceptible to DENV infection than mature DC and DENV
62 infect these cells independent of Fc γ receptor [4,5,6]. pDCs are not found to be DENV targets *in vitro*
63 as significantly lower levels of DENV replication was observed when compared to moDC [7,8].
64 Previous experiments proved LCs in epidermis to be the primary targets of DENV in skin, however,
65 subsequent experiments suggested that DENV is probably released in the dermal layer of the skin
66 affecting its resident cells first [9,10,4]. Hence, the route by which epidermal resident cells (LC and
67 keratinocytes) get infected is still unclear. Studies done by Duangkhae 2018 showed that DENV likely
68 mediates LC migration to the dermis where these cells further get infected [11]. Also, studies done
69 by other groups indicate dermal cDCs and macrophages to play more significant role than LCs in
70 DENV spread [10,12].

71 The most extensively studied DC receptors are DC-SIGN(CD209) [13,14,4,15], Mannose receptor
72 (MR) [16,17], Langerins [18,19] and Fc γ receptors [20,21,7]. Other potential receptors expressed in DC
73 include TIM3, TIM4 [22,23,24] and AXL [25].

74 DC SIGN, a C type lectin pathogen recognition receptor, is highly expressed in immature DCs
75 like resident dermal DCs (CD14+), monocyte derived DC in the dermis, DC in lymph node, thymus
76 and lungs, myeloid DCs in blood and also in dermal and alveolar macrophages (7,10,13,15,26,8,27).
77 Although, in presence of Ca²⁺ the 'carbohydrate recognition domain' (CRD) of DC-SIGN has been
78 shown to interact with the high mannose oligosaccharides present in Asn67 residue of DENV E, DC
79 SIGN is also reported to bind to the other branched glycans containing terminal fucose residues
80 [28,29,30,31,32].

81 The importance of DC-SIGN as a DENV entry receptor was highlighted when its expression in
82 various cells lines rendered these cells permissive to DENV infection [13,15,28]. The mechanism by
83 which DC-SIGN mediates DENV entry was further studied by Liu et al 2017. By using live cell
84 imaging on DENV infected MX-DC-SIGN cells, the researchers showed that DC-SIGN and DENV
85 after forming a complex migrate towards clathrin coated pits and get endocytosed. However, the
86 mutants lacking the internalization domain (DC-SIGN-3A) or the one containing a partial
87 cytoplasmic domain (DC-SIGN- Δ 35) when expressed in MX-DC-SIGN cells still favoured DENV
88 infection, although to a lesser extent than the intact DC-SIGN. Other groups also found similar results
89 when mutant DC-SIGN (without cytoplasmic tail) in HEK-293T cells could still enhance DENV
90 infection [28,33]. Hence, the role of DC-SIGN in mediating DENV infection has been interjected to be
91 an attachment factor for DENV, which concentrate the virus on the cell surface and present it to a
92 mysterious receptor, further ushering DENV to the endosomal compartment [13].

93 Studies done by Cerny et al 2014 on single cell suspensions of healthy human skin discovered
94 LCs, dermal macrophages and CD14+DCs to be highly infected as compared to the other subsets of
95 dermal cDCs (CD1c+ and CD141+DCs) [9]. On further study, they showed that CD14+ DC being

96 highly susceptible to DENV infection, expressed both DC-SIGN (CD209) and mannose receptor (MR)
97 (CD206). However, CD1c+ DC showing lesser susceptibility to DENV expressed only mannose
98 receptor (CD206) and CD141+ DC being least susceptible expressed none of these receptors. Dermal
99 macrophages also express both DC-SIGN (CD209) and mannose receptor (CD206) on their cell
100 surface and hence are highly permissive to DENV [27]. Hence, both receptors (DC-SIGN and MR)
101 seem to work together to mediate DENV entry in these cells. MR is constitutively internalised via
102 endocytic or phagocytic pathway and hence may act as DENV entry receptor for DC and
103 macrophages, whereas DC SIGN is mostly confined to the cell surface and work as an important
104 attachment factor [17].

105 Langerin (CD207) is another C type lectin receptor similar to DC-SIGN and is predominantly
106 expressed in Langerhans cells in the epidermis [18,19]. It also specifically recognises mannose and
107 fucose glycans along with GlcNAc moieties on the DENV E protein [34]. DENV uses this receptor to
108 gain access to LCs in skin where it proliferates for further dissemination [4].

109 TIM3 and TIM4 are another group of receptors that are expressed on the surface of DC and might
110 facilitate DENV entry in these cells [22,23]. TIM3 and TIM4 have been observed to play an important
111 role in phagocytosis of apoptotic cells and TIM-4 was particularly detected in immature DCs and
112 macrophages of spleen [24]. These receptors have been studied to mediate DENV entry in transfected
113 cell lines where TIM3 has been perceived to play a less significant role than TIM1 and TIM4 in
114 mediating the entry process [35]. TAM receptors (TYRO3, AXL and MER) particularly AXL, also
115 involved in the uptake of the apoptotic cells, has been observed to be expressed on the surface of
116 Langerhans cells early during its differentiation and might play a significant role in mediating DENV
117 infection in these cells [25].

118 Antibody dependent enhancement (ADE) is the mechanism by which the heterologous
119 antibodies (IgG), irrespective of the neutralizing capabilities surround DENV during the secondary
120 infection and present it to an Fc γ R bearing cells to enhance DENV infection [36,8,
121 37,38,39,40,41,42,43].

122 In case of ADE, mature DC and macrophages showed enhanced infectivity at a low
123 concentration of heterologous antibodies. Hence, immature DCs (iDC) and mature DCs (maDC) were
124 observed to play a distinct role in primary and secondary infection and cell tropism was found to be
125 slightly different in two conditions. In primary infection iDC were infected most followed by maDC
126 and macrophage, whereas in secondary infection, in presence of heterologous anti DENV antibodies
127 the macrophage is infected most followed by maDC and iDC [44].

128 Fc γ RIIa and Fc γ RIIb are the two receptors that are expressed on the hematopoietic cells and
129 interact with the opsonising antibodies (IgG) surrounding DENV particle for its enhanced
130 phagocytosis. The LCs, immature moDCs and dermal DCs as they express high levels of langerins
131 (LC) and DC-SIGN (moDCs and dermal DCs) respectively, become primary targets of DENV in
132 absence of enhancing antibodies [4,15,5]. Despite, they do not play any role in ADE even though they
133 express Fc γ RIIA highly as elevated levels of expressed DC-SIGN plays a dominant role and mediate
134 DENV entry in these cells [7,20]. In contrast to this, mature moDCs gets infected by DENV moderately
135 during primary infection as they express lesser amount of DC-SIGN but inflated levels of Fc γ RIIA on
136 their surface, showing significantly high capacity for ADE [20,7].

137 **Monocytes and macrophages**

138 Monocytes and macrophages are the primary targets of DENV along with the Dendritic Cells. It
139 has been reported that macrophages in lymphoid and non lymphoid tissues are the major targets of
140 DENV replication during later period of infection. They are also the primary reservoirs of DENV after
141 its dissemination from the skin. DENV was found to replicate in macrophages of different organs
142 namely, kupffer cells in liver, alveolar macrophages in lungs, macrophages of lymphoid organs
143 (spleen, lymph node and thymus) dermal macrophages, microglial cells and monocytes in peripheral
144 blood [45,46,37,47,9,48].

145 Experiments in mice indicate that after DENV infects skin, the inflammatory Ly6C+ monocytes
146 were recruited to the skin replenishing LCs in epidermis and Ly6C+ CD11b+ moDC in the dermis

147 which were efficiently targeted by DENV [7,10]. These studies indicate that possibly this observation
148 holds true in case of humans, where blood derived monocytes migrate to the site of infection in skin
149 and act as another reservoir of DENV for replication [9,7,10,49].

150 Cell surface receptors that help in DENV tropism in monocytes and macrophage include
151 mannose receptor (CD205) [16,17,50], CD14-associated protein [51,52], HSP70/HSP90 [53,54], DC-
152 SIGN(CD209) [7,10,15,50] and CD300a [55,56], AXL and TIM4 [57,22,24] and PD1[58].

153 Mannose receptor (MR) is another C type lectin, found in both macrophages and DC and has a
154 multi domain structure [16,17,50]. MR binds specifically to the carbohydrate moieties terminating in
155 mannose, fucose and N-acetyl Glucosamine (NAG) residues as found in Asn67 of DENV E
156 glycoproteins [16,17,50]. Mannose receptor has been shown by Miller et al 2008 to be an important
157 receptor for DENV entry in human macrophages. Pretreatment of monocytes with type 2 cytokines
158 enhanced the surface expression of MR and DC SIGN on human monocyte derived macrophages
159 which led to the increased percentage of infected cells. DC-SIGN, which is known to play a role in
160 DENV attachment to DC, also has some role to play in macrophage susceptibility to DENV, probably
161 acting as an additional attachment factor for these cells [17]. However, Dermal and Alveolar
162 macrophages are the only macrophages that possess cell surface DC-SIGN and hence may mediate
163 DENV infection in these cells in cooperation with MR [26,27].

164 CD14 is a cell surface glycoprotein, expressed predominantly on the surface of monocytes and
165 macrophages and possesses a high affinity for LPS [59]. It remains associated with the low affinity
166 transmembrane proteins that show signal transducing properties [52,59]. *In vitro* infection model
167 studies on monocytes and macrophages have shown a role of CD14 or its associated molecules in
168 DENV mediated infection, as pre treatment of these cells with LPS before DENV infection suppressed
169 the infection markedly [51,52]. The decrease in infection was inspected not due to LPS mediated
170 release of cytokines but due to blockage of CD14 and its associated cell surface molecules by LPS [52].
171 However, the outcome of LPS pre treatment before DENV infection was perceived to show both
172 strain and cell specific effect on DENV infection [51].

173 Cell surface proteins like HSP70 and HSP90 are known to be a part of the receptor complex
174 helping in DENV tropism in human monocytes and neurons [53,54]. Hsp90 and Hsp70 (74/84 kDa
175 molecule) isolated from neuroblastoma cell line SK-SY-5Y, U937 cells and human peripheral
176 monocytes/macrophages, was observed to interact with DENV-2 strain 16681 E protein and
177 pretreatment with anti Hsp 70/anti Hsp90 antibodies reduced DENV infection in these cells [54].

178 It has been observed that phospholipid receptors like TIM, TAM and CD300a expressed on the
179 surface of phagocytes recognise Phospholipids like phosphatidyl ethanolamine(PE) and
180 phosphatidyl serine(PS) expressed on the surface of apoptotic bodies and mediate their phagocytosis
181 [24,35,57,25,56]. This mechanism has been exploited by DENV to interact with such receptors as the
182 DENV membranes express such phospholipids which it acquires during the process of virus budding
183 from ER [35,55,60]).

184 The T cell/transmembrane, immunoglobulin, and mucin (TIM) gene family include 3 members
185 in humans (TIM-1, TIM-3, and TIM-4) and these receptors are expressed in different cells with slightly
186 different functions. TIM1 is highly expressed on T-helper 2 (Th2) cells and are important for T cell
187 activation, TIM 3 is highly expressed on Th1, Tc1 cells and DC mediating phagocytosis of the
188 apoptotic cells and cross-presentation of antigen and TIM4 is expressed in antigen presenting cells
189 (APC) and has a role in phagocytosis of apoptotic cells and immune tolerance [22,23]

190 TIM 1, TIM 4 and to a lesser extent TIM3 were found to enhance mosquito-derived DENV2-JAM
191 infection when expressed in 3T3 and Vero cell lines and a direct interaction between TIM receptors
192 and DENV virions was observed in a Ca²⁺ dependent manner [35]. Furthermore, the authors showed
193 that TIM receptors (TIM 1 and TIM 4) expressing 293T cells recognised PS expressed on DENV virion
194 envelope to mediate its entry in the cells. The role of TIM1 in DENV infection was inferred by
195 Meertens et al 2012 and Dejarnac et al 2018 where the significance of TIM1 and its cytoplasmic tail in
196 mediating DENV infection was assessed [35,60]. TIM1 knockout cells like A549 and Huh7.5 showed
197 significantly less DENV2 infection [60] but TIM1 mutant without cytoplasmic tail (TIM-1 Δcyt) had
198 no such effect when transfected in 293T cells [35]. Hence TIM1 is important for enhancing DENV

199 infection but its cytoplasmic tail has no or minimal role in enhancing DENV infection. Nevertheless,
200 it plays a vital role in mediating DENV internalization by clathrin mediated endocytosis [60].

201 The TAM protein family is a group of three receptor protein tyrosine kinases that recognises PS
202 expressed on the surface of apoptotic cells indirectly via TAM ligands (Gas6 and ProS) and are
203 expressed on phagocytes particularly DC and macrophages [35,57,61,55]. TYRO3 and AXL are two
204 such TAM receptors that are known to recognise apoptotic cells and also enhance DENV infection
205 [35]. Furthermore, TIM1 and AXL have been observed to be expressed in DENV permissive cell lines
206 like A549, Vero, Cos-7 and Huh7 5.1 cells but are absent in cells which are non permissive to DENV
207 like 293T, U937, or RAJI cells [35]. Hence both the receptors (TIM1 and AXL) may act cooperatively
208 and complementarily to positively influence DENV binding in the cells.

209 Recently a phospholipid receptor CD-300a, expressed on the surface of mast cells, monocytes
210 and monocyte derived macrophages (MDM) has been observed to act as a receptor of DENV [62, 55].
211 It directly interacts with PE and to a lesser extent with PS expressed on the surface of DENV and
212 enhances its entry in these cells [55,56]. On expression of CD300a in HEK 293T cell line and in HeLa
213 cells, the DENV2 infection was highly enhanced suggesting its importance as an attachment receptor
214 but does not play a major role in mediating DENV entry [55]. In the same study it was shown that
215 although CD300a was expressed in monocytes, mast cells and monocyte derived macrophages,
216 CD300a could increase DENV infection only in MDM and was ineffective in case of other two cells
217 suggesting its cell specific action.

218 Other chaperones like Protein disulphide isomerase (PDI) has also been shown to enhance the
219 DENV binding to the cell surface THP-1 and also in Endothelial cells [58,63]. PDI is an ER resident
220 chaperone but has been found to be localised in various other cellular regions like nuclear envelope,
221 cytoplasm, Golgi, secretory vesicles, and plasma membrane [64]. PDI was found to be upregulated
222 during DENV infection in THP1 cell lines and was observed to be associated with the lipid rafts for
223 an efficient interaction with DENV. Hence, PDI plays a role in mediating DENV interaction with the
224 susceptible cells but further studies are needed to decipher its exact role in DENV tropism as the
225 authors failed to show direct interaction of PDI with DENV E protein [58].

226 Although Two Fc γ receptors particularly Fc γ RI(CD64) and Fc γ RII(CD32) have been shown to
227 mediate ADE in phagocytic cells *in vitro*, Fc γ RIIA(CD32) was found to enhance DENV infection more
228 efficiently than Fc γ RIA (CD64) [65,37,66]. However, cells which facilitate ADE particularly primary
229 monocytes, express both the cell surface receptors [37]. Fc γ RII has two subsets that play different
230 roles in ADE by either activating or inhibiting the process, particularly Fc γ RIIA which enhances ADE
231 and Fc γ RIIB which abolishes ADE and both these molecules are known to be expressed in ADE
232 supporting cells- monocytes, macrophage and moDC (mature and immature) [7,20]. Nonetheless, it
233 has been perceived that these cells, specifically mature moDC enlarge the ratio of Fc γ RIIA/Fc γ RIIB
234 to facilitate DENV entry during ADE [20]. ADE hypothesis has been widely studied for Monocytes,
235 macrophages, mature DC (moDC) and mast cells but there is a high possibility of B cells and
236 Endothelial cells being involved in ADE, as they express Fc γ R on their cell surface [67,68,42,43,69].
237 Monocytes play a less significant role as primary targets for DENV since they express lesser amount
238 of DC-SIGN compared to DCs but has a major role to play in secondary infection during ADE, due
239 to high levels of Fc γ R expression [7,10,37].

240 **Mast cells and Basophils**

241 Mast cells found in dermis of the skin are important for the surveillance of the immune system
242 and on encountering DENV it gets degranulated, secreting various cytokines (IL-1, IL-6, TNF- α , IFN- α)
243 and chemokines(CCL5, CXCL12, and CX3CL1). This further leads to an antiviral state in nearby
244 cells, generating an inflammatory response and cells like NK and NKT get recruited to combat
245 DENV [70]. Various reports indicate the susceptibility of mast cells to DENV tropism and hence, mast
246 cells are one among other cells that support DENV entry and replication [71,11]. Primary human skin
247 mast cells were identified to support DENV2 infection as seen by qRT-PCR and are also among the
248 initial targets of DENV in skin [71]. Furthermore, skin explants when infected with DENV2 showed
249 mast cells to be among the susceptible cell population showing productive infection in the dermis

250 [11]. DENV2 was also observed in the secretory granules of these cells and were highly infectious to
251 the uninfected cells [71]. Moreover, when these extracellular granules were injected in mice footpad,
252 the DENV containing granules travelled through lymph to draining lymph nodes (DLN) and spleen
253 leading to further virus dissemination. Hence, they discovered a novel mechanism used by DENV
254 to spread in the host, starting from the skin to the various lymphoid organs, apart from being carried
255 by the infected immune cells.

256 Mast cells are Fc γ R bearing cells that express all the Fc γ Rs (Fc γ RI, Fc γ RII, and Fc γ RIII), as
257 observed in various cells like human cord blood derived mast cells (CBMCs) that express all the 3
258 Fc γ Rs, while Fc γ RII was prominently expressed on the surface of human mast cell lines HMC-1 and
259 KU812 [42]. Experiments done by various groups in human mast cell-like line HMC-1 and KU812
260 successfully inferred the importance of heterologous antibodies to mediate DENV entry in human
261 mast cells via Fc γ RII receptors [72,42,43]. These cells were infected with DENV alone or DENV with
262 antibodies and a significant infection was observed in presence of antibodies [42,43].

263 Apart from Fc receptors, TIM1 and TIM3 are also found to be expressed in mouse peritoneal mast
264 cells and bone marrow-derived cultured mast cells (BMCMCs) [22,73]. These can be potential
265 receptors used by DENV for its entry in mast cells.

266 T cells and B cells

267 B cells and T cells have been studied by various laboratories to ascertain their roles in supporting
268 DENV replication, but contradictory results leave it an open question to address. *In vitro* studies done
269 on B cell lines (Raji cells, Wil 2WT, BM and LK63, Daudi and 8866) and primary B cells derived from
270 healthy human Peripheral blood mononuclear cells (PBMC) strongly state its potential role in DENV
271 replication, both in presence and absence of heterologous antibodies [74,75,51,76]. Also, blood
272 samples of DHF patients revealed the presence of DENV antigen in B lymphocytes [77] but mere
273 presence of DENV antigen does not prove DENV replication in these cells. In the humanized mouse
274 model study, lymphocytes (both B and T cells) were DENV infected at an earlier stage of infection (1-
275 2 dpi and 3 dpi respectively) and B cells produced important proinflammatory cytokines (IL-6 and
276 TNF- α) similar to monocytes and macrophage [39]. Furthermore, *in vivo* experiment done on DENV
277 infected BALB/c mice revealed the presence of NS3, E and prM in B cell follicles particularly in the
278 germinal center (GC), B cells of DLN, indicating viral replication in these cells [67]. Some groups of
279 researchers found naive primary human T cells (CD8+, CD4+) derived from PBMCs of healthy
280 individuals and human Th and Tc clones (JK44, JK49, CB2.8 and CB6.17, HSB-2, Molt-4 and Jurkat) to
281 be DENV permissive, producing new infectious virions from the infected cells [79,80,51,76].

282 In contrast to this, other groups found no evidence of DENV replication in primary B and T cells
283 in healthy human PBMCs or in splenic B and T cells as seen by FACS analysis, RT PCR and plaque
284 assay [46,37]. *In vivo* studies found no DENV antigen in B or T cells of infected human tissues as
285 detected via Immuno-histochemistry (IHC) and *in situ* hybridization (ISH) techniques [45]. Viral NS3
286 specific immune staining of infected AG129 mice and human tissue samples also indicated absence
287 of the DENV specific protein in lymphocytes of all the tissues [81]. According to Kou et al 2008, T or
288 B cells are not DENV permissive both in absence or presence of facilitating anti-E antibodies. The
289 same group showed it to be true for spleen derived mononuclear cells where splenic macrophages
290 were infected both in presence and absence of anti-DENV antibodies but T or B cells were uninfected
291 [46]. Theofilopoulos et al 1976 also reported similar results, where T cell lines lymphoblast MOLT-4
292 and primary T cells from healthy human PBMC were not found to support DENV replication but
293 DENV was observed to adsorb on the cell surface early after infection. Hence, the author proposed T
294 cells to possess the DENV receptor but due to some other intrinsic or extrinsic factors, DENV failed
295 to enter or replicate in these cells. Schmid et al 2014b further studied the epidermal CD45+ $\gamma\delta$ T cells
296 in *Ifnar*^{-/-} mice after intra dermal inoculation of DENV2 and found these cells to be non-permissive
297 to DENV.

298 Contradictory reports have also been obtained regarding receptor usage of DENV for T cell
299 entry. Heparan sulphate was identified to be the putative receptor on T cells that mediated DENV


300 entry [79] but Ohmann et al 2000 found no significant role of heparan sulfate in promoting DENV
301 binding to these cells [51].

302 Work done on T helper (Th) cells revealed the involvement of cell surface PDI in facilitating HIV
303 entry in these cells [82]. Studies done on PDI in relation to DENV entry have indicated it to likely
304 play a role in DENV tropism, making it a yet another putative receptor for T cells [63] that needs
305 further research. TIM1 and TIM 3 have been noted to be expressed primarily on the surface of Th2
306 cells and Th1 /Tc1 cells respectively, having a role to play in both their activation and apoptosis
307 [22,23,24,35]. Hence, these receptors might play a role in DENV entry in human T cells. No receptor
308 has yet been identified to be responsible for DENV entry in B cells. However, Fc γ R might be utilized
309 by DENV to gain access in these cells [67,69].

310 Discussion

311 The human immune cells that have been most extensively studied to support DENV are DC,
312 monocytes and tissue macrophages [4,5,6,45,46,37,47,9,48]. However, recent studies have identified
313 mast cells to be the new targets of DENV in humans and their potential in acting as viral replicating
314 machinery [71,11]. Mast cells may be inferred to be among the early targets of DENV in skin along
315 with the known hosts of DENV: DCs and dermal macrophages [71,11]. Future studies will elaborate
316 our understanding of DENV tropism and explore other unknown targets of DENV in the host.
317 Controversial role of lymphoid cells (T and B) in DENV tropism and replication also needs further
318 exploration.

319 Multiple receptors associated with the DENV tropism in host and vector has been studied to
320 better understand their individual role in facilitating DENV entry. However, all studies indicate that
321 DENV seems to utilise multiple receptors/co receptors to gain access to the host cells and that not a
322 single receptor can be conclusively declared to be solely involved in DENV ingress. These
323 observations raise multiple possibilities regarding DENV-cell interaction at the entry point and the
324 different modes of entry inside the cells (fig 1). A) DENV either attaches to the cell surface via its
325 receptors/ co receptors followed by the dissolution of the membrane (cellular and virion) at the
326 attachment site, which further leads to the entry of the nucleocapsid in the cytoplasm directly,
327 without involvement of any vesicles [83,84] (fig 1a). B) DENV binds to the receptor/co receptors
328 forming DENV-receptor complex first, followed by its diffusion to the pre formed clathrin coated pit
329 for endocytosis [85] (fig 1b). C) DENV first interacts with multiple low affinity co receptors like DC-
330 SIGN, Langerin, CD300A, CD-14, Heparan sulphate, PDI etc via roll over mechanism to toughen its
331 hold on the cells, followed by its interaction with the less abundant but high affinity receptor located
332 near the pre-existing clathrin coated pit or within the pit after which DENV enters possibly via
333 receptor mediated endocytosis [85] (fig 1c). D) Interaction with the receptors/co receptors in lipid
334 rafts might mediate signal transduction to enhance the availability of the main receptor on the cell
335 surface or might lead to caveolae mediated endocytosis (fig 1d). E) DENV might also follow the
336 dynamin dependent, clathrin independent mode of endocytosis to enter the cells [86] (fig 1e). There
337 also lies a possibility that DENV deploys all these receptors in a cell specific manner to approach the
338 cell for a productive infection and as such does not depend on any one receptor for the entry. If this
339 is true then it would be intriguing to know what the underlying factors behind such cell specific
340 interaction are. How does DENV recognize different receptors in a cell specific way?



341

342

343

344

345

346

347

348

349

350

351

352

353

354

Figure 1. An overview of the different routes of DENV entrance in susceptible cells via multiple receptors/co receptors: a) Direct entry of DENV in cells. a1) DENV first forms a complex with receptors/co receptors and then a2) fuse with the cell membrane releasing the nucleocapsid (DENV NC) in the cytoplasm. b), c) Receptor mediated endocytosis of DENV in cells in which b1) DENV after interacting with receptors and co receptors diffuse along the membrane and enter through preformed clathrin coated pit further leading to the b2) endosome formation or c1) DENV might possibly interact with co receptors by rolling over the cell surface until it reaches to the main receptor present near or within the preformed clathrin coated pit after which it gets c2) endocytosed. d) Lipid rafts may also play an important role in DENV tropism by providing the platform for DENV interaction with multiple receptors and co receptors, which in turn may lead to d1) caveolae mediated endocytosis or d2) downstream signalling to enhance the receptor expression at the cell surface. e) Non classical, dynamin dependent but clathrin independent endocytosis is another route of entry that DENV might follow for ingress in cells.

355

356

357


358

359

360

361

Furthermore, as mentioned in figure 2 and Table 1, DENV interacts with the different receptors in a cell specific manner which further complicates the identification of a possible common receptor mandatory for the DENV entry process. MR in monocytes/macrophages and DC and recently TIM1 receptors have been shown to be important for DENV entry in these cells and these might not just be acting as co receptors/attachment factors for DENV [8, 15,17,35,60]. Further studies are needed to confirm their universal role in the ingress of DENV in susceptible cells and the detailed mechanism of the process.



362

363

364

365

Figure 2: Multiple receptors used by DENV for entry in the host. PS/PE: phosphatidyle serine and phosphatidyl ethanolamine on DENV membrane. prM: precursor membrane of DENV. E: Envelope protein of DENV.

Receptors mediating DENV tropism.	Susceptible cells in humans expressing the receptor	References
DC-SIGN	<ul style="list-style-type: none"> • Dermal Dendritic cells (CD14+) • Dermal macrophages • Alveolar macrophages • Dendritic cells in lungs • Dendritic cells in lymph nodes • Myeloid DCs in blood 	<ul style="list-style-type: none"> • Schaeffer et al 2015, Cerny et al 2014 • Schaeffer et al 2015 • Soilleux et al 2003 • Soilleux et al 2003 • Soilleux et al 2003 • Sun et al 2009, Tassaneeritthep et al 2003, Wu et al 2000
Langerin	<ul style="list-style-type: none"> • Langerhans cells 	<ul style="list-style-type: none"> • Wu et al 2000 • Cerny et al 2014
Mannose receptor	<ul style="list-style-type: none"> • Dermal Dendritic cells (CD14+, CD 1c+) • Macrophages 	<ul style="list-style-type: none"> • Schaeffer et al 2015, Miller et al 2008
TIM	<ul style="list-style-type: none"> • Dendritic cells • Macrophages • T cells 	<ul style="list-style-type: none"> • Freeman et al 2010, Manzanet et al 2009, Kobayashi et al 2007 • Freeman et al 2010, Manzanet et al 2009 • Freeman et al 2010, Manzanet et al 2009, Kobayashi et al 2007, Meertens et al 2012
TAM	<ul style="list-style-type: none"> • Langerhans cells • Macrophages 	<ul style="list-style-type: none"> • Bauer et al 2012, Lemke et al 2008 • Lemke et al 2008 • Borrego et al 2013, Carnec et al 2015
CD-300a	<ul style="list-style-type: none"> • Mast cells • Monocyte derived macrophages • Blood monocytes 	<ul style="list-style-type: none"> • Borrego et al 2013, Carnec et al 2015 • Borrego et al 2013, Carnec et al 2015 • Borrego et al 2013, Carnec et al 2015

FcγR	<ul style="list-style-type: none"> • Mast cells • Macrophages • Blood monocytes • Conventional DC • B cells 	<ul style="list-style-type: none"> • Brown et al 2006, King et al 2000, Brown et al 2010 • Boonnak et al 2008, Schmid et al 2014b • Kou et al 2008, Boonnak et al 2008, Schmid et al 2014b • Boonnak et al 2008, Schmid et al 2014b • Gergely et al 1977
Protin Disulfide Isomerase (PDI)	<ul style="list-style-type: none"> • Blood Monocytes • T cells 	<ul style="list-style-type: none"> • Diwaker et al 2015 • Barbouche et al 2005
Heat shock proteins (HSP70, HSP 90)	<ul style="list-style-type: none"> • Blood monocytes 	<ul style="list-style-type: none"> • Valle et al 2005
Heparan Sulfate	<ul style="list-style-type: none"> • T cells 	<ul style="list-style-type: none"> • Silveira et al 2018, Ohmann et al 2000
CD-14	<ul style="list-style-type: none"> • Macrophages • Blood monocytes 	<ul style="list-style-type: none"> • Wright et al 1990 • Wright et al 1990

366 **Table 1. Outline of the various receptors that have been studied in context of DENV entry in susceptible**
 367 **immune cells. .**

368 In relation to DENV tropism, researchers emphasized on the importance of E protein in
 369 interacting with the host receptors, but the role of M protein has long been neglected. M protein,
 370 another important component of the DENV envelope, lies in close proximity to E protein and act as
 371 its chaperone to maintain proper E protein confirmation and govern its antigenicity [87,88].
 372 Furthermore, the glycosylation pattern of M protein has not been studied in great detail but
 373 glycosylation at Asn64-69 residues have been detected in different DENV serotypes, particularly at
 374 Asn 68 residue [89,16]. Hence, there lies a possible role of M protein in mediating DENV interaction
 375 with the host cell receptors either indirectly or directly. If it does perform any role in DENV-receptor
 376 interaction then what exactly is its role? Does it interact with any host receptor/co receptor directly
 377 to strengthen the interaction of DENV with the target cell or it indirectly facilitates DENV E
 378 interaction with the receptors?

379 The true potential of DENV E in recognizing the host receptors needs to be further explored.
 380 Studies done on mosquito derived DENV E stated that apart from mannose residues at Domain II
 381 (DII) Asn67 residue, fucose, sialic acid, GalNAc and GlcNAc have also been observed at this position
 382 along with sialic acid at Domain I(DI) Asn153 site [90]. Therefore, role of these glycan moieties in
 383 recognizing host receptors need further investigation and their binding partners may play an equally
 384 important role in attaching DENV to the cell surface. What other residues in E get glycosylated and
 385 how that affects DENV tropism in host and vector is still an open question to address.

386 **Author contributions:** Ms Feroza Begum (FB), Mr Sandeepan Das (SD) and Ms Debica Mukherjee (DM) wrote
 387 the manuscript. Dr. Upasana Ray (UR) wrote and edited the manuscript. SD and DM contributed equally and
 388 should be considered as joint second authors.

389 **References:**

- 390 1. Souza HF, da Silva Almeida B, Boscardin SB. Early dengue virus interactions: the role
 391 of dendritic cells during infection. *Virus research*. 2016 Sep 2;223:88-98.
- 392 2. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus
 393 life cycle. *Nature Reviews Microbiology*. 2005 Jan;3(1):13.
- 394 3. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view.
 395 *Clinical microbiology reviews*. 2009 Oct 1;22(4):564-81.
- 396 4. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK,
 397 Filgueira L, Marovich MA, Wong HK, Blauvelt A. Human skin Langerhans cells are
 398 targets of dengue virus infection. *Nature medicine*. 2000 Jul;6(7):816.
- 399 5. Marovich M, Grouard-Vogel G, Eller M, Tassaneetrithep B, Bix D, Hayes C,
 400 Schlesinger-Frankel S, Louder M, Mascola J, Sun W, Wu SJ. Human dendritic cells as
 401 targets of dengue virus infection. *Journal of Investigative Dermatology Symposium*
 402 *Proceedings* 2001 Dec 1; 6(3):219-224

- 403 6. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW, Lai JH. Infection of human
404 dendritic cells by dengue virus causes cell maturation and cytokine production. *The*
405 *Journal of Immunology*. 2001 Feb 1; 166(3):1499-506.
- 406 7. Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: targets
407 of virus replication and mediators of immunity. *Frontiers in immunology*. 2014a Dec
408 17;5: 647.
- 409 8. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z,
410 Subramanian H, Porter KR, Sun W, Burgess TH. Functional characterization of ex vivo
411 blood myeloid and plasmacytoid dendritic cells after infection with dengue virus.
412 *Virology*. 2009 Jan 20; 383(2):207-15.
- 413 9. Cerny D, Haniffa M, Shin A, Bigliardi P, Tan BK, Lee B, Poidinger M, Tan EY, Ginhoux
414 F, Fink K. Selective susceptibility of human skin antigen presenting cells to productive
415 dengue virus infection. *PLoS pathogens*. 2014 Dec 4;10(12):e1004548.
- 416 10. Schmid MA, Harris E. Monocyte recruitment to the dermis and differentiation to
417 dendritic cells increases the targets for dengue virus replication. *PLoS pathogens*. 2014b
418 Dec 4;10(12):e1004541.
- 419 11. Duangkhae P, Erdos G, Ryman KD, Watkins SC, Falo Jr LD, Marques Jr ET, Barratt-
420 Boyes SM. Interplay between keratinocytes and myeloid cells drives dengue virus spread
421 in human skin. *Journal of Investigative Dermatology*. 2018 Mar 1;138(3):618-26.
- 422 12. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster
423 JG, Engleman EG. Langerhans cells renew in the skin throughout life under steady-state
424 conditions. *Nature immunology*. 2002 Dec;3(12):1135..
- 425 13. Liu P, Ridilla M, Patel P, Betts L, Gallichotte E, Shahidi L, Thompson NL, Jacobson K.
426 Beyond attachment: Roles of DC-SIGN in dengue virus infection. *Traffic*. 2017
427 Apr;18(4):218-31.
- 428 14. Sun P, Kochel TJ. The battle between infection and host immune responses of dengue
429 virus and its implication in dengue disease pathogenesis. *The Scientific World Journal*.
430 2013;2013.
- 431 15. Tassaneeritthep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W,
432 Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM. DC-SIGN
433 (CD209) mediates dengue virus infection of human dendritic cells. *Journal of*
434 *Experimental Medicine*. 2003 Apr 7;197(7):823-9.
- 435 16. Yap SS, Nguyen-Khuong T, Rudd PM, Alonso S. Dengue virus glycosylation: what do
436 we know?. *Frontiers in microbiology*. 2017 Jul 25;8: 1415.
- 437 17. Miller JL, M deWet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM,
438 Gordon S. The mannose receptor mediates dengue virus infection of macrophages. *PLoS*
439 *pathogens*. 2008 Feb 8;4(2):e17.
- 440 18. Valladeau J, Duvert-Frances V, Pin JJ, Dezutter-Dambuyant C, Vincent C, Massacrier
441 C, Vincent J, Yoneda K, Banchereau J, Caux C, Davoust J. The monoclonal antibody
442 DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly
443 internalized from the cell surface. *European journal of immunology*. 1999
444 Sep;29(9):2695-704.
- 445 19. Ingber A. Langerhans cell receptors. *Dermatologic Clinic*. 2007 Oct 25 (4):559–562.
- 446 20. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF,
447 Yuwono D, Puthavathana P, Marovich MA. Role of dendritic cells in antibody-
448 dependent enhancement of dengue virus infection. *Journal of virology*. 2008 Apr
449 15;82(8):3939-51.
- 450 21. Boonnak K, Dambach KM, Donofrio GC, Tassaneeritthep B, Marovich MA. Cell type
451 specificity and host genetic polymorphisms influence antibody-dependent enhancement
452 of dengue virus infection. *Journal of virology*. 2011 Feb 15;85(4):1671-83.

- 453 22. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell
454 surface phosphatidylserine receptors that regulate innate and adaptive immunity.
455 *Immunological reviews*. 2010 May;235(1):172-89.
- 456 23. Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role
457 of TIM molecules. *Immunological reviews*. 2009 May;229(1):259-70.
- 458 24. Kobayashi N, Karisola P, Peña-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ,
459 Nagumo H, Chernova I, Zhu B, Sharpe AH. TIM-1 and TIM-4 glycoproteins bind
460 phosphatidylserine and mediate uptake of apoptotic cells. *Immunity*. 2007 Dec
461 21;27(6):927-40.
- 462 25. Bauer T, Zagórska A, Jurkin J, Yasmin N, Köffel R, Richter S, Gesslbauer B, Lemke G,
463 Strobl H. Identification of Axl as a downstream effector of TGF- β 1 during Langerhans
464 cell differentiation and epidermal homeostasis. *Journal of Experimental Medicine*. 2012
465 Oct 22;209(11):2033-47.
- 466 26. Soilleux EJ. DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-
467 SIGN-related (DC-SIGNR): friend or foe?. *Clinical science*. 2003 Apr 1;104(4):437-46.
- 468 27. Schaeffer E, Flacher V, Papageorgiou V, Decossas M, Fauny JD, Krämer M, Mueller
469 CG. Dermal CD14+ dendritic cell and macrophage infection by dengue virus is
470 stimulated by interleukin-4. *Journal of Investigative Dermatology*. 2015 Jul
471 1;135(7):1743-51.
- 472 28. Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier JL, Rey
473 FA, Desprès P, Arenzana-Seisdedos F, Amara A. Dendritic cell-specific intercellular
474 adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of
475 dengue virus infection is independent of DC-SIGN internalization signals. *Journal of
476 Biological Chemistry*. 2005 Jun 24;280(25):23698-708.
- 477 29. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, Gregorio
478 GG, Hendrickson WA, Kuhn RJ, Rossmann MG. Cryo-EM reconstruction of dengue
479 virus in complex with the carbohydrate recognition domain of DC-SIGN. *Cell*. 2006 Feb
480 10;124(3):485-93.
- 481 30. Dubayle J, Vialle S, Schneider D, Pontvianne J, Mantel N, Adam O, Guy B, Talaga P.
482 Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's
483 tetravalent CYD dengue vaccine. *Vaccine*. 2015 Mar 10;33(11):1360-8.
- 484 31. Smit J, Moesker B, Rodenhuis-Zybert I, Wilschut J. Flavivirus cell entry and membrane
485 fusion. *Viruses*. 2011;3(2):160-71.
- 486 32. Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, Taylor ME, Weis WI,
487 Drickamer K. Structural basis for distinct ligand-binding and targeting properties of the
488 receptors DC-SIGN and DC-SIGNR. *Nature structural & molecular biology*. 2004
489 Jul;11(7):591.
- 490 33. Acosta EG, Talarico LB, Damonte EB. Cell entry of dengue virus. *Future Virol*. 2008;
491 3:471-479.
- 492 34. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping
493 immune responses. *Nature Reviews Immunology*. 2009 Jul;9(7):465.
- 494 35. Meertens L, Carnec X, Lecoïn MP, Ramdasi R, Guivel-Benhassine F, Lew E, Lemke G,
495 Schwartz O, Amara A. The TIM and TAM families of phosphatidylserine receptors
496 mediate dengue virus entry. *Cell host & microbe*. 2012 Oct 18;12(4):544-57.
- 497 36. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis.
498 *Comparative immunology, microbiology and infectious diseases*. 2007 Sep 1;30(5-
499 6):329-40.
- 500 37. Kou Z, Quinn M, Chen H, Rodrigo WS, Rose RC, Schlesinger JJ, Jin X. Monocytes, but
501 not T or B cells, are the principal target cells for dengue virus (DV) infection among
502 human peripheral blood mononuclear cells. *Journal of medical virology*. 2008
503 Jan;80(1):134-46.

- 504 38. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. *New England Journal of*
505 *Medicine*. 2012 Apr 12;366(15):1423-32.
- 506 39. Mota J, Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human
507 dengue fever. *PloS one*. 2011 Jun 10;6(6):e20762.
- 508 40. Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y,
509 Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, Wilson PC. B cell
510 responses during secondary dengue virus infection are dominated by highly cross-
511 reactive, memory-derived plasmablasts. *Journal of virology*. 2016 Jun 15;90(12):5574-
512 85.
- 513 41. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-
514 dependent enhancement of microbial infection in macrophages: disease regulation by
515 immune complexes. *The Lancet infectious diseases*. 2010 Oct 1;10(10):712-22.
- 516 42. Brown MG, King CA, Sherren C, Marshall JS, Anderson R. A dominant role for FcγRII
517 in antibody-enhanced dengue virus infection of human mast cells and associated CCL5
518 release. *Journal of leukocyte biology*. 2006 Dec 1;80(6):1242-50.
- 519 43. King CA, Marshall JS, Alshurafa H, Anderson R. Release of vasoactive cytokines by
520 antibody-enhanced dengue virus infection of a human mast cell/basophil line. *Journal of*
521 *virology*. 2000 Aug 1;74(15):7146-50.
- 522 44. Flipse J, Torres S, Dios-Toro M, van der Ende-Metselaar H, Herrera-Rodriguez J,
523 Urcuqui-Inchima S, Huckriede A, Rodenhuis-Zybert IA, Smit JM. Dengue tropism for
524 macrophages and dendritic cells: the host cell effect. *Journal of General Virology*. 2016
525 Jul 1;97(7):1531-6.
- 526 45. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in
527 naturally infected human tissues, by immunohistochemistry and in situ hybridization.
528 *The Journal of infectious diseases*. 2004 Apr 15;189(8):1411-8.
- 529 46. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, Jin X.
530 Primary human splenic macrophages, but not T or B cells, are the principal target cells
531 for dengue virus infection in vitro. *Journal of virology*. 2007 Dec 15;81(24):13325-34.
- 532 47. Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S. Trafficking
533 and replication patterns reveal splenic macrophages as major targets of dengue virus in
534 mice. *Journal of virology*. 2012 Nov 15;86(22):12138-47.
- 535 48. Jhan MK, Tsai TT, Chen CL, Tsai CC, Cheng YL, Lee YC, Ko CY, Lin YS, Chang CP,
536 Lin LT, Lin CF. Dengue virus infection increases microglial cell migration. *Scientific*
537 *reports*. 2017 Mar 7;7(1):91.
- 538 49. Ginhoux F, Tacke F, Angeli V, Bogunovic M, Loubreau M, Dai XM, Stanley ER,
539 Randolph GJ, Merad M. Langerhans cells arise from monocytes in vivo. *Nature*
540 *immunology*. 2006 Mar;7(3):265.
- 541 50. Lo YL, Liou GG, Lyu JH, Hsiao M, Hsu TL, Wong CH. Dengue virus infection is
542 through a cooperative interaction between a mannose receptor and CLEC5A on
543 macrophage as a multivalent hetero-complex. *PLoS One*. 2016 Nov
544 10;11(11):e0166474.
- 545 51. Bielefeldt-Ohmann H, Meyer M, Fitzpatrick DR, Mackenzie JS. Dengue virus binding
546 to human leukocyte cell lines: receptor usage differs between cell types and virus strains.
547 *Virus research*. 2001 Jan 1;73(1):81-9.
- 548 52. Chen YC, Wang SY, King CC. Bacterial lipopolysaccharide inhibits dengue virus
549 infection of primary human monocytes/macrophages by blockade of virus entry via a
550 CD14-dependent mechanism. *Journal of virology*. 1999 Apr 1;73(4):2650-7.
- 551 53. Reyes-del Valle J, Salas-Benito J, Soto-Acosta R, del Angel RM. Dengue virus cellular
552 receptors and tropism. *Current Tropical Medicine Reports*. 2014 Mar 1;1(1):36-43.

- 553 54. Reyes-del Valle J, Chávez-Salinas S, Medina F, Del Angel RM. Heat shock protein 90
554 and heat shock protein 70 are components of dengue virus receptor complex in human
555 cells. *Journal of virology*. 2005 Apr 15;79(8):4557-67.
- 556 55. Carnec X, Meertens L, Dejarnac O, Perera-Lecoin M, Hafirassou ML, Kitaura J et al.
557 The phosphatidylserine and phosphatidylethanolamine receptor CD300a binds dengue
558 virus and enhances infection. *Journal of virology*. 2015 Jan 1; 90(1):92-102.
- 559 56. Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F. Human CD300a
560 binds to phosphatidylethanolamine and phosphatidylserine, and modulates the
561 phagocytosis of dead cells. *Blood*. 2012 Mar 22;119(12):2799-809.
- 562 57. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. *Nature Reviews*
563 *Immunology*. 2008 May;8(5):327.
- 564 58. Diwaker D, Mishra KP, Ganju L, Singh SB. Protein disulfide isomerase mediates dengue
565 virus entry in association with lipid rafts. *Viral immunology*. 2015 Apr 1;28(3):153-60.
- 566 59. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for
567 complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science*. 1990 Sep
568 21;249(4975):1431-3.
- 569 60. Dejarnac O, Hafirassou ML, Chazal M, Versapuech M, Gaillard J, Perera-Lecoin M,
570 Umana-Diaz C, Bonnet-Madin L, Carnec X, Tinevez JY, Delaugerre C. TIM-1
571 ubiquitination mediates dengue virus entry. *Cell reports*. 2018 May 8;23(6):1779-93.
- 572 61. Fernández-Fernández L, Bellido-Martín L, de Frutos PG. Growth arrest-specific gene 6
573 (GAS6). *Thrombosis and haemostasis*. 2008;100(10):604-10.
- 574 62. Borrego F. The CD300 molecules: an emerging family of regulators of the immune
575 system. *Blood*. 2013 Mar 14;121(11):1951-60.
- 576 63. Wan SW, Lin CF, Lu YT, Lei HY, Anderson R, Lin YS. Endothelial cell surface
577 expression of protein disulfide isomerase activates β 1 and β 3 integrins and facilitates
578 dengue virus infection. *Journal of cellular biochemistry*. 2012 May;113(5):1681-91.
- 579 64. Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-
580 ER locations and functions. *Journal of cellular physiology*. 2002 Nov;193(2):154-63.
- 581 65. Rodrigo WS, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of
582 dengue virus immune complex infectivity mediated by signaling-competent and
583 signaling-incompetent human Fc γ RIA (CD64) or Fc γ RIIA (CD32). *Journal of virology*.
584 2006 Oct 15;80(20):10128-38.
- 585 66. Puerta-Guardo H, Mosso C, Medina F, Liprandi F, Ludert JE, del Angel RM. Antibody-
586 dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich
587 membrane microdomains. *Journal of General Virology*. 2010 Feb 1;91(2):394-403.
- 588 67. Yam-Puc JC, Cedillo-Barrón L, Aguilar-Medina EM et al. The cellular bases of antibody
589 responses during dengue virus infection. *Front Immunol*. 2016; **7(218)**:1-12.
- 590 68. Zellweger RLM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal
591 endothelial cells in a mouse model Of antibody-induced severe dengue disease. *Cell Host*
592 *Microbe*. 2010; **7**:128–139.
- 593 69. Gergely P, Bakács T, Cornain S, Klein E. Fc receptors on human blood B
594 lymphocytes. *Clin Exp Immunol*. 1977 Apr;28(1):99-102.
- 595 70. John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, Vasudevan SG, Abraham SN.
596 Immune surveillance by mast cells during dengue infection promotes natural killer (NK)
597 and NKT-cell recruitment and viral clearance. *Proceedings of the National Academy of*
598 *Sciences*. 2011 May 31;108(22):9190-5.
- 599 71. Troupin A, Shirley D, Londono-Renteria B, Watson AM, McHale C, Hall A, Hartstone-
600 Rose A, Klimstra WB, Gomez G, Colpitts TM. A role for human skin mast cells in
601 dengue virus infection and systemic spread. *The Journal of Immunology*. 2016 Dec
602 1;197(11):4382-91.

- 603 72. Brown MG, Hermann LL, Issekutz AC, Marshall JS, Rowter D, Al-Afif A, Anderson R.
604 Dengue virus infection of mast cells triggers endothelial cell activation. *Journal of*
605 *virology*. 2011 Jan 15;85(2):1145-50.
- 606 73. Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, DeKruyff RH, Saito H, Galli SJ. TIM-
607 1 and TIM-3 enhancement of Th2 cytokine production by mast cells. *Blood*. 2007 Oct
608 1;110(7):2565-8.
- 609 74. Lin YW, Wang KJ, Lei HY, Lin YS, Yeh TM, Liu HS, Liu CC, Chen SH. Virus
610 replication and cytokine production in dengue virus-infected human B lymphocytes.
611 *Journal of virology*. 2002 Dec 1;76(23):12242-9.
- 612 75. Theofilopoulos AN, Brandt WE, Russell PK, Dixon FT. Replication of dengue-2 virus
613 in cultured human lymphoblastoid cells and subpopulations of human peripheral
614 leukocytes. *The Journal of Immunology*. 1976 Sep 1;117(3):953-61.
- 615 76. Kurane I, Kontny U, Janus J, Ennis FA. Dengue-2 virus infection of human mononuclear
616 cell lines and establishment of persistent infections. *Archives of virology*. 1990 Mar
617 1;110(1-2):91-101.
- 618 77. Boonpucknavig S, Bhamarapravati N, Nimmannitya S, Phalavadhana A, Siripont J.
619 Immunofluorescent staining of the surfaces of lymphocytes in suspension from patients
620 with dengue hemorrhagic fever. *The American journal of pathology*. 1976 Oct;85(1):37.
- 621 78. Yam-Puc JC, García-Cordero J, Calderón-Amador J, Donis-Maturano L, Cedillo-Barrón
622 L, Flores-Romo L. Germinal center reaction following cutaneous dengue virus infection
623 in immune-competent mice. *Frontiers in immunology*. 2015 Apr 24;6:188.
- 624 79. Silveira GF, Wowk PF, Cataneo AH, dos Santos PF, Delgobo M, Stimamiglio MA, Sarzi
625 ML, Thomazelli AP, Conchon-Costa I, Pavanelli WR, Antonelli LR. Human T
626 lymphocytes are permissive for dengue virus replication. *Journal of virology*. 2018 May
627 15;92(10):e02181-17.
- 628 80. Mentor NA, Kurane I. Dengue virus infection of human T lymphocytes. *Acta Virologica*.
629 1997 Jun;41(3):175-6.
- 630 81. Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, Beatty PR, Harris E.
631 Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-
632 specific immunostaining. *The American journal of tropical medicine and hygiene*. 2009
633 Mar 1;80(3):416-24.
- 634 82. Barbouche R, Lortat-Jacob H, Jones IM, Fenouillet E. Glycosaminoglycans and protein
635 disulfide isomerase-mediated reduction of HIV Env. *Molecular pharmacology*. 2005 Apr
636 1;67(4):1111-8.
- 637 83. Hase T, Summers PL, Eckels KH. Flavivirus entry into cultured mosquito cells and
638 human peripheral blood monocytes. *Archives of virology*. 1989 Mar 1;104(1-2):129-43.
- 639 84. Lim HY, Ng ML. A different mode of entry by dengue-2 neutralisation escape mutant
640 virus. *Archives of virology*. 1999 May 1;144(5):989-95.
- 641 85. van der Schaar HM, Rust MJ, Chen C, van der Ende-Metselaar H, Wilschut J, Zhuang
642 X, Smit JM. Dissecting the cell entry pathway of dengue virus by single-particle tracking
643 in living cells. *PLoS pathogens*. 2008 Dec 19;4(12):e1000244.
- 644 86. Acosta EG, Castilla V, Damonte EB. Alternative infectious entry pathways for dengue
645 virus serotypes into mammalian cells. *Cellular microbiology*. 2009 Oct;11(10):1533-49.
- 646 87. Heinz FX, Stiasny K, Püschner-Auer G, Holzmann H, Allison SL, Mandl CW, Kunz C.
647 Structural changes and functional control of the tick-borne encephalitis virus
648 glycoprotein E by the heterodimeric association with protein prM. *Virology*. 1994 Jan
649 1;198(1):109-17.
- 650 88. Aruna R. Review on dengue viral replication, assembly and entry into the host
651 cells. *International Journal Of Current Microbiology And Applied Sciences*. 2014 Nov
652 11; 3(11): 1025-1039.

- 653 89. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Desprès P. α -Glucosidase
654 inhibitors reduce dengue virus production by affecting the initial steps of virion
655 morphogenesis in the endoplasmic reticulum. *Journal of Virology*. 2000 Jan
656 1;74(1):564-72.
- 657 90. Lei Y, Yu H, Dong Y, Yang J, Ye W, Wang Y, Chen W, Jia Z, Xu Z, Li Z, Zhang F.
658 Characterization of N-glycan structures on the surface of mature dengue 2 virus derived
659 from insect cells. *PLoS One*. 2015 Jul 24;10(7):e0132122.